If you are 18 or older with a BMI of 35 or greater, a history of calcium oxalate kidney stones, and are desiring to lose weight, you may be eligible to participate in a research study. The goal of this study is to better understand calcium oxalate kidney stone disease and how weight loss might impact urinary oxalate and kidney stone risk. The study requires eating a study diet for 5 days with a one-day long visit both before and after weight loss, participating in a 14-week long weight loss program with the aid of Optifast VLCD® shakes, collecting 24-hr urines, blood samples, and stool samples. Participants will have the opportunity to be compensated up to $920 for participation in the program over the 6 -8-month participation time frame. They will also receive all Optifast products and study meals for free! For more information email kidneystoneresearch@uabmc.edu
Published in
Clinical Trials
Adult Volunteers ages 18-75 are needed for a study examining the relationship between oxalate handling in the blood and urine in persons with and without chronic kidney disease. The study involves consuming prepared meals over 5 days twice, one-day long visit in our clinical research unit, and the collection of urine and blood. Compensation up to $360. For more information, call 205-224-7324 or email kidneystoneresearch@uabmc.edu.
Published in
Clinical Trials
Healthy individuals ages 18-75 are needed for a study examining the relationship between oxalate handling in the blood and urine in persons with and without chronic kidney disease. The study involves consuming prepared meals over 5 days twice, one-day long visit in our clinical research unit, and the collection of urine and blood. Compensation up to $360. For more information, call 205-224-7324 or email kidneystoneresearch@uabmc.edu.
Published in
Clinical Trials
Overweight/Obese adult volunteers needed for study If you are between the ages of 18 -89 yrs and have a body mass index > 30 kg/m2 you may be eligible to participate in a study exploring the reason why individuals who have high BMI have an increased risk of forming calcium oxalate kidney stones. Participation involves eating study-provided meals for 4 days, providing urine and blood samples. Study meals are provided free of charge and additional compensation up to $140 is offered. For more information call 205-934-5712 or email kidneystone@uabmc.edu or kidneystoneresearch@uabmc.edu
Published in
Clinical Trials
Adults with Type 2 Diabetes needed for a study If you are between the ages of 18 -89 yrs and have type 2 diabetes you may be eligible to participate in a study exploring the reason why individuals who have diabetes have an increased risk of forming calcium oxalate kidney stones. Individuals who are obese, overweight, or normal weight are all welcome to the study. Participation involves eating study-provided meals for 4 days, providing urine and blood samples. Study meals are provided free of charge and additional compensation up to $140 is offered. For more information, call 205-934-5712 or email kidneystone@uabmc.edu or kidneystoneresearch@uabmc.edu.
Published in
Clinical Trials
You may be eligible to take part in this study if you have previously had a heart attack (myocardial infarction) or brain attack (stroke) or have been diagnosed with poor circulation. If you have reduced kidney function or if you have inflammation in your blood vessels ? The University of Alabama at Birmingham, Department of Nutrition Sciences, is conducting a 4 year research study to look if an investigational medicine ,called ‘ziltivekimab’ can be used to treat people with cardiovascular disease, chronic kidney disease and inflammation. Qualified participants will receive study drug at no cost and may be compensated for time and travel. For more information, and to see if you might be eligible to join, contact (205) 996-4015 or email at ccnrn@uab.edu.
Published in
Clinical Trials
Adults ages 18-89 with history of kidney stones needed for a study Individuals ages 18-89 years with a history of Calcium Oxalate kidney stones, are needed for a study exploring factors that impacting oxalate metabolism in kidney stone formers. The study involves consuming prepared meals over 4 days and collecting urine and blood. Compensation up to $140. For more information, call 205-934-5712 or email kidneystone@uabmc.edu or kidneystoneresearch@uabmc.edu.
Published in
Clinical Trials
The purpose of this Phase II adaptive study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of PF006730512 following multiple intravenous infusion in adult subjects with primary FSGS. You may qualify if you are a male or female ages 18-65, with an eGFR >45, a UPCR >1.5 g/g, also a non-responder to a single treatment regimen for FSGS, considered intolerant to an Immunosuppressant and are a non-responder to a single treatment regimen, or considered intolerant to an Immunosuppressant and are naïve to other Immunosuppressant treatment regimens for FSGS. Must discontinue steroid treatment or tapered down to a stable prednisone dose 7.5 mg per day or other steroid equivalents to achieve a stable dose before the lead-in period. Participants must be willing and able to comply with scheduled visits, must comply with birth control regimen or have proof of postmenopausal status. If you are interested please contact Teresa Chacana at (205) 934-7649
Published in
Clinical Trials
The nefIgArd clinical research study is for patients diagnosed with primary IgA Nephropathy, IgAN, who are at risk of developing end-stage kidney disease even though they are taking medication to preserve kidney function. IgAN, also known as Berger’s disease, is a kidney disease where the antibody called immunoglobulin A, IgA, embeds itself into the kidneys. This causes inflammation, which can affect the kidney’s ability to filter the blood. Some cases of IgAN progress slowly without symptoms or go into remission, while others lead to end-stage kidney failure. Currently, there are no drugs approved specifically to treat IgAN. The purpose of the nefIgArd study is to look at the safety, tolerability, and effectiveness of the study drug Nefecon compared to placebo in patients with IgAN, who are at risk of progressing to end-stage kidney disease To learn more about study participation, contact: Ciara Mitchell at 205-975-9491.
Published in
Clinical Trials
You may qualify to participate in an active-control treatment study of the efficacy and safety of Sparsentan, funded by Retrophin Incorporated. Qualifying participants must be over the age of 19 years old, not on dialysis or have received a previous transplant, and have had a renal biopsy confirming diagnosis. Participants will be compensated. For more information, please contact Laura Latta via phone number 205-975-8638 or email at Alatta@uabmc.edu.
Published in
Clinical Trials
You may qualify to participate in a 4-month research study, funded by the National Institute of Health (NIH), on blood vessel health in patients with chronic kidney disease. Qualifying participants must: Be between the ages of 19 and 65 Not on Dialysis Have moderate stage of kidney disease with 26%-60% function. Participants will be compensated. For more information, please contact UAB Division of Nephrology at 205-934-7295. Or email Salam Madi salammadi@uabmc.edu
Published in
Clinical Trials
Do you have kidney disease? You may qualify to participate in a 4-month research study, funded by the National Institute of Health, on blood vessel health in patients with chronic kidney disease. Qualifying participants must 1) Be age 19-65, 2) Not be on dialysis, 3) Have a moderate stage of kidney disease (25-60% function). Participants will be compensated. For more information, please contact UAB Division of Nephrology 205-934-7295. Or email Salam Madi at salammadi@uabmc.edu
Published in
Clinical Trials
Healthy Adult Volunteers ages 18-89 needed for study Healthy individuals ages 18-89 are needed for a study exploring the reason why some individuals have an increased risk of forming calcium oxalate kidney stones. You don’t have to have kidney stones to participate. The study involves consuming prepared meals over 4 days and collecting urine and blood. Compensation up to $140. For more information, call 205-934-5712 or email kidneystone@uabmc.edu or kidneystoneresearch@uabmc.edu.
Published in
Clinical Trials
In our study of patients with resistant hypertension, we have shown that vascular function improves with the use of spironolactone, a mineralocorticoid receptor antagonist. Spironolactone has also been shown to reduce urinary protein loss in patients with chronic kidney disease. We are looking for men and women, ages 19-65, with Stage III CKD, non-diabetic or who have controlled diabetes, and who are not currently taking spironolactone or amiloride. The study lasts 16 weeks, with six visits, and compensation and parking will be provided for all six visits. If interested, please contact Cassidy Clevenger at (205) 934-6745.
Published in
Clinical Trials
You may qualify to participate in an international research study to evaluate the safety and tolerability of an investigational drug for patients with type 2 diabetes and kidney disease. Are you at least 18 years old? Do you have type 2 diabetes mellitus and a clinical diagnosis of kidney disease? Eligible study participants will receive study medications, blood pressure checks, physical exams, laboratory tests and ECG at no cost. Participants will be reimbursed for time and travel. For more information, call the UAB Hypertension Program at 934-9281 or e-mail ccc-hlnresearch@mail.ad.uab.edu.
Published in
Clinical Trials
